Management of Palpitations in CKD with Elevated Creatinine and Borderline Potassium

Immediate Diagnostic Evaluation

The KDIGO 2024 guidelines recommend a standardized diagnostic package for new arrhythmias in CKD patients, including 12-lead ECG, laboratory testing for thyroid function, serum electrolytes, and complete blood count, and transthoracic echocardiography to assess left ventricular size and function, left atrial size, valvular disease, and right heart function 1, 2, 3
Obtain an immediate 12-lead ECG to assess for arrhythmia, followed by laboratory testing for thyroid function, serum electrolytes, and full blood count, while simultaneously evaluating for underlying cardiac disease 1, 2, 3

With a potassium of 4.7 mEq/L and creatinine of 4.75, this patient is at high risk for progression to dangerous hyperkalemia, and potassium measurements have significant variability due to diurnal and seasonal variation, plasma versus serum samples, and medication effects 4, 5
Implement dietary potassium restriction immediately, limiting intake of foods rich in bioavailable potassium, with a target potassium intake of less than 2,000-3,000 mg daily, and avoid salt substitutes containing potassium 6, 4, 7
Review all medications for potassium-retaining effects, including RAAS inhibitors, mineralocorticoid receptor antagonists, NSAIDs, and potassium-sparing diuretics 8, 5, 7

Use medical therapy, such as beta-blockers, to control ventricular rate to less than 90 bpm at rest to decrease symptoms and related complications, and consider dose adjustments necessary for CKD stage 1, 2, 3
For thromboprophylaxis, use non-vitamin K antagonist oral anticoagulants in preference to warfarin for CKD G1-G4, with careful dose adjustment and monitoring required at CKD G4-G5 1, 3

Conduct thorough medication reconciliation, including herbal products and supplements that can raise potassium levels, and be aware that cardiac biomarkers may be elevated due to reduced GFR rather than exclusively from cardiac damage 7, 8
If RAAS inhibitors are being used, hyperkalemia can often be managed by measures to reduce serum potassium levels rather than decreasing the dose or stopping RAAS inhibitors, and continue RAAS inhibitors unless serum creatinine rises by more than 30% within 4 weeks or uncontrolled hyperkalemia develops despite medical treatment 5, 4

Consider newer potassium binders, such as patiromer or sodium zirconium cyclosilicate, to allow continuation of cardioprotective RAAS inhibitor therapy if potassium rises above 5.0 mEq/L despite dietary restriction and medication adjustment 9, 10
Patiromer effectively reduces serum potassium in CKD patients, with mean reductions of 0.65 mEq/L in mild hyperkalemia and 1.23 mEq/L in moderate-to-severe hyperkalemia at 4 weeks 9, 10